ClinicalTrials.gg
CompletedNCT05858736PRESERVE-009Updated Sep 14, 2026

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

A Phase 1 interventional study of AI-061 in Melanoma, Non Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by OncoC4, Inc.. Completed at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by OncoC4, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 285 studies in Melanoma with a site in Australia — 45 open to participants now, 89 under way, 19 of them phase 3. Melanoma · Australia.

Enrollment
239th of 272
18 · median 160
Started
2023
with 17 others
Phase 1
61 of 285
7 open now
Registered
241st of 285
by date

Among the 285 studies in Melanoma with a site in Australia, this one is the 239th largest by enrollment of the 272 interventional ones that give a count, is one of 18 that started in 2023, is one of 61 in phase 1, and was the 241st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

45 of the 285 studies in Melanoma with a site in Australia are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 285 studies in Melanoma with a site in Australia, or all of them as a file.
02

Study summary

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

Read the detailed description

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. Both CTLA-4 and PD-1 are known targets for immunotherapy. This Phase I study will test 3 fixed doses of AI-061 given as intravenous (IV) infusion, once every 21 days (q3w): 200 mg (consists of 100 mg ONC-392 and 100 mg AI-025), 400 mg and 600 mg. The target population is patient with advanced or metastatic solid tumors that progressed on standard care systemic therapy or intolerable to standard of care systemic therapy. The primary objective is to determine the maximum toxicity dose (MTD) or the Recommended Phase 2 dose (RP2D). The study design follows the classical 3+3 design for Phase 1 study that will enroll up to 18 subjects. The treatment will be terminated when patient has intolerable toxicity, or death, or disease progression, or complete of 17 cycles of treatment in approximate 1 year, whichever come first.

03

Conditions studied

  • Melanoma
  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • High Grade Serous Adenocarcinoma of Ovary
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Cervical Cancer
  • Renal Cell Carcinoma
  • Bladder Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Colorectal Cancer
  • Anal Cancer
  • Hepatocellular Carcinoma
  • Bile Duct Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is greater or 18 years of age on the day of signing the .
  2. All genders. Female subject with pregnancy potential must have a negative pregnancy test.
  3. Patient must have a performance status of less than or equal to 1 on the Performance Scale.
  4. Patients must have a histological or cytological diagnosis of solid tumors and have progressive locally advanced or disease.
  5. as determined by v1.1 (either tumor lesion or lymph node lesion or both): Tumor mass: Must be accurately measurable in at least 1 dimension (longest diameter to be recorded) with a minimum size of: 10 mm by computed tomography (CT) scan (CT scan slide thickness must be less than 5 mm). Or: 20 mm by chest X-ray (if clearly defined and surrounded by aerated lung).

    Malignant lymph nodes: greater than or equal to 15 mm in short axis when assessed by CT scan (CT scan slice thickness must be \<5 mm). The measurement should be two dimensions at axial plane. The short axis should be in perpendicular to long diameter.

  6. Patient must have adequate organ function as indicated by the laboratory values. LDH less than or equal to .
  7. Voluntary agreement to participate as evidenced by written informed consent.
  8. Female patient: agreement on methods.
  9. Male patient: agreement on contraceptive methods.
  10. greater than or equal to 12 weeks.

Exclusion criteria

Exclusion Criteria:

Patients who have not recovered to v5.0 less than or equal toGrade 1 from an adverse event (AE) due to cancer therapeutics except endocrinopathy or the chemotherapy-associated peripheral neuropathy (motor or sensory) that has recovered to CTCAE v5.0 less than or equal to Grade 2 will be allowed. The for cancer therapeutic drugs should be 21 days prior to the first AI-061 dose for chemotherapy, radiation, or targeted therapy or 28 days prior to the first AI-061 administration for monoclonal antibody therapy. Best supportive care, such as thyroxine, insulin, replacement treatment, blood transfusion, and therapy for non-cancer conditions are allowed.

2. Patients who are currently enrolled in any other clinical trial testing an agent or device, or with concurrent other systemic cancer therapeutics.

3. Patients who are on chronic systemic steroid therapy at doses higher than 10 mg/day prednisone or equivalent within 7 days before the first treatment.

4. Patients who have active or . 5. Patients who have an active infection requiring systemic IV antibiotics within 14 days prior to administration of AI-061. Regular treatment of urinary tract infection (UTI) and/or topical treatment are allowed.

6. Patients who, in the opinion of the treating Investigator, have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or make study participation not in the best interest of the patient. The investigator should discuss this with the Sponsor.

7. Patients with known psychiatric or substance abuse disorders that in the opinion of the investigator, would interfere with cooperation with the requirements of the trial.

8. Patients who are pregnant or breastfeeding.

9. Patients with active diseases that require treatment other than 10 mg per day or lower prednisone. Patients with inflammatory bowel disease or myasthenia gravis will be excluded.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Level 1

    AI-061, 200 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.

    Drug: AI-061

  • Experimental
    Level 2

    AI-061, 400 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.

    Drug: AI-061

  • Experimental
    Level 3

    AI-061, 600 mg, intravenous infusion, Q3W, up to 17 cycles or approximately 1 year.

    Drug: AI-061

Interventions

  • DrugAI-061

    A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.

    Also known as: Anti-PD-1 and anti-CTLA-4 in 1:1 co-formulation

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    The number of subjects who have Dose limiting toxicity (DLT) as defined by protocol DLT criteria during the first cycle of study drug, AI-061, administration.

    Time frame: 21 days after first treatment

  2. Maximum Toxicity Dose (MTD)

    Maximal tolerable dose (MTD), the study drug, AI-061, dose level that has two out of six subjects who have DLT.

    Time frame: 21 day after first treatment

  3. Recommended Phase II Dose (RP2D)

    Recommended Phase II Dose (RP2D), the study drug, AI-061, dose level that is one level below MTD, or an intermediate dose level that below MTD and pre-specified in protocol. This dose level will be the RP2D.

    Time frame: 21 days after first treatment

  4. Incidence of treatment emergent adverse events (TEAE)

    Incidence of treatment emergent adverse events (TEAE) according to CTCAE v5.0.

    Time frame: From the day with first treatment to 90 days after the last treatment.

Secondary outcomes

  1. Cmax of AI-061

    The highest Serum concentration of AI-061 after IV infusion at cycle 1 and cycle 3 dosings from different timepoints after drug administration.

    Time frame: Frequent PK samplings in cycle 1 and cycle 3, pre-dose and post-dose samples in other cycles and End of Treatment. Up to 1 year.

  2. The serum half-life of AI-061

    To determine the drug concentration in serum samples that are taken in various timepoints during the treatment in order to calculate drug half life.

    Time frame: Frequent PK samplings in cycle 1 and cycle 3, pre-dose and post-dose samples in other cycles and End of Treatment. Up to 1 year.

  3. Objective Response Rate (ORR)

    Objective Response Rate (ORR), evaluated by investigators on radiological images according to RECIST 1.1.

    Time frame: Up to 1 year.

  4. Progression free survival (PFS)

    Progression free survival (PFS), the event is the time that diseased progressed evaluated by investigators or death occurs.

    Time frame: Up to 1 year.

  5. Overall survival (OS),

    Overall survival (OS), the event is the time that all cause death occurs.

    Time frame: Up to 1 year.

07

Study locations

5 sites
  • St. Vincent's Private Hospital
    Darlinghurst, New South Wales 2010, Australia
  • Mater Misericordiae Ltd.
    Brisbane, Queensland 4006, Australia
  • Tasman Oncology Research
    Southport, Queensland 4120, Australia
  • Cancer Research SA
    Adelaide, South Australia 5000, Australia
  • Southern Oncology Clinical Research Unit
    Bedford Park, South Australia 5042, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jul 2026, 36 months.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 36 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 15, 2023
StartActual
Jul 11, 2023
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858736
Lead sponsor
OncoC4, Inc.
Collaborators
OncoC4 AU Pty Ltd, Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
May 15, 2023
Start date
Jul 11, 2023
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Sep 14, 2026

Study contacts

Rohit Joshi, MD
principal investigator · Cancer Research South Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion